154 related articles for article (PubMed ID: 23597200)
61. A methodological approach to unravel organ-specific breast cancer metastasis.
Nola S; Sin S; Bonin F; Lidereau R; Driouch K
J Mammary Gland Biol Neoplasia; 2012 Jun; 17(2):135-45. PubMed ID: 22628182
[TBL] [Abstract][Full Text] [Related]
62. Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma.
Gao W; Bing X; Li M; Yang Z; Li Y; Chen H
Med Oncol; 2013 Jun; 30(2):546. PubMed ID: 23536000
[TBL] [Abstract][Full Text] [Related]
63. Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment.
Yao HP; Feng L; Zhou JW; Zhang RW; Wang MH
Am J Cancer Res; 2016; 6(5):937-56. PubMed ID: 27293990
[TBL] [Abstract][Full Text] [Related]
64. Mammary fat of breast cancer: gene expression profiling and functional characterization.
Wang F; Gao S; Chen F; Fu Z; Yin H; Lu X; Yu J; Lu C
PLoS One; 2014; 9(10):e109742. PubMed ID: 25291184
[TBL] [Abstract][Full Text] [Related]
65. The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1.
Zhang B; Fu D; Xu Q; Cong X; Wu C; Zhong X; Ma Y; Lv Z; Chen F; Han L; Qian M; Chin YE; Lam EW; Chiao P; Sun Y
Nat Commun; 2018 Apr; 9(1):1723. PubMed ID: 29712904
[TBL] [Abstract][Full Text] [Related]
66. Blocking Short-Form Ron Eliminates Breast Cancer Metastases through Accumulation of Stem-Like CD4+ T Cells That Subvert Immunosuppression.
Lai SA; Gundlapalli H; Ekiz HA; Jiang A; Fernandez E; Welm AL
Cancer Discov; 2021 Dec; 11(12):3178-3197. PubMed ID: 34330779
[TBL] [Abstract][Full Text] [Related]
67. On mammary gland growth factors: roles in normal development and in cancer.
Hung MC
Cold Spring Harb Perspect Biol; 2012 Aug; 4(8):a013532. PubMed ID: 22855727
[TBL] [Abstract][Full Text] [Related]
68. RON kinase isoforms demonstrate variable cell motility in normal cells.
Greenbaum A; Rajput A; Wan G
Heliyon; 2016 Sep; 2(9):e00153. PubMed ID: 27656686
[TBL] [Abstract][Full Text] [Related]
69. Alpha-actinin 4 and tumorigenesis of breast cancer.
Hsu KS; Kao HY
Vitam Horm; 2013; 93():323-51. PubMed ID: 23810014
[TBL] [Abstract][Full Text] [Related]
70. Chk2*1100delC Acts in synergy with the Ron receptor tyrosine kinase to accelerate mammary tumorigenesis in mice.
Meyer SE; Peace BE; Bahassi el M; Kavanaugh GM; Wagh PK; Robbins SB; Yin M; Wells SI; Zinser GM; Stambrook PJ; Waltz SE
Cancer Lett; 2010 Oct; 296(2):186-93. PubMed ID: 20434834
[TBL] [Abstract][Full Text] [Related]
71. Protein interacting with C alpha kinase 1 (PICK1) is involved in promoting tumor growth and correlates with poor prognosis of human breast cancer.
Zhang B; Cao W; Zhang F; Zhang L; Niu R; Niu Y; Fu L; Hao X; Cao X
Cancer Sci; 2010 Jun; 101(6):1536-42. PubMed ID: 20384629
[TBL] [Abstract][Full Text] [Related]
72. Computational analysis of receptor tyrosine kinase inhibitors and cancer metabolism: implications for treatment and discovery of potential therapeutic signatures.
Li J; Halfter K; Zhang M; Saad C; Xu K; Bauer B; Huang Y; Shi L; Mansmann UR
BMC Cancer; 2019 Jun; 19(1):600. PubMed ID: 31208363
[TBL] [Abstract][Full Text] [Related]
73. Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer.
Jin N; Bi A; Lan X; Xu J; Wang X; Liu Y; Wang T; Tang S; Zeng H; Chen Z; Tan M; Ai J; Xie H; Zhang T; Liu D; Huang R; Song Y; Leung EL; Yao X; Ding J; Geng M; Lin SH; Huang M
Nat Commun; 2019 Jun; 10(1):2701. PubMed ID: 31221965
[TBL] [Abstract][Full Text] [Related]
74. Ron receptor tyrosine kinase signaling as a therapeutic target.
Benight NM; Waltz SE
Expert Opin Ther Targets; 2012 Sep; 16(9):921-31. PubMed ID: 22834780
[TBL] [Abstract][Full Text] [Related]
75. All-trans retinoic acid and protein kinase C α/β1 inhibitor combined treatment targets cancer stem cells and impairs breast tumor progression.
Berardi DE; Ariza Bareño L; Amigo N; Cañonero L; Pelagatti MLN; Motter AN; Taruselli MA; Díaz Bessone MI; Cirigliano SM; Edelstein A; Peters MG; Diament M; Urtreger AJ; Todaro LB
Sci Rep; 2021 Mar; 11(1):6044. PubMed ID: 33723318
[TBL] [Abstract][Full Text] [Related]
76. Hornerin, an S100 family protein, is functional in breast cells and aberrantly expressed in breast cancer.
Fleming JM; Ginsburg E; Oliver SD; Goldsmith P; Vonderhaar BK
BMC Cancer; 2012 Jun; 12():266. PubMed ID: 22727333
[TBL] [Abstract][Full Text] [Related]
77. Targeting protein tyrosine kinase 6 in cancer.
Gilic MB; Tyner AL
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188432. PubMed ID: 32956764
[TBL] [Abstract][Full Text] [Related]
78. Exploratory drug discovery in breast cancer patients: A multimodal deep learning approach to identify novel drug candidates targeting RTK signaling.
Karampuri A; Kundur S; Perugu S
Comput Biol Med; 2024 May; 174():108433. PubMed ID: 38642491
[TBL] [Abstract][Full Text] [Related]
79. Evidence for 2-Methoxyestradiol-Mediated Inhibition of Receptor Tyrosine Kinase RON in the Management of Prostate Cancer.
Batth IS; Huang SB; Villarreal M; Gong J; Chakravarthy D; Keppler B; Jayamohan S; Osmulski P; Xie J; Rivas P; Bedolla R; Liss MA; Yeh IT; Reddick R; Miyamoto H; Ghosh R; Kumar AP
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33673346
[TBL] [Abstract][Full Text] [Related]
80. Inhibition of receptor tyrosine kinases in combination with chemotherapy for the treatment of breast cancer.
Moulder SL; Craft BS; Hortobagyi GN
Anticancer Agents Med Chem; 2008 Jun; 8(5):481-7. PubMed ID: 18537531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
